Is it time to revisit residual renal function in haemodialysis? (Review article)

Nephrology

Volumn 12, Issue 3, 2007, Pages 209-217

  Ng, Tsun G ^a   Johnson, David W ^a   Hawley, Carmel M ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Dialysis adequacy; Haemodialysis; Peritoneal dialysis; Residual renal function

Indexed keywords

BUFFER; DIALYSIS FLUID;

CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CREATININE CLEARANCE; DIALYSIS MEMBRANE; FUNCTIONAL ASSESSMENT; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOFILTRATION; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; PERITONEAL DIALYSIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; RESIDUAL RENAL FUNCTION; REVIEW; SURVIVAL; ULTRAFILTRATION; URINE VOLUME;

HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MEMBRANES, ARTIFICIAL; PERITONEAL DIALYSIS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 34248194926     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2007.00795.x     Document Type: Review

References (79)

1. Diaz-Buxo JA, Lowrie EG, Lew NL, Zhang HY, Zhu XF, Lazarus JM. Associates of mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance. Am. J. Kidney Dis. 1999 33 : 523 34.
2. Termorshuizen F, Korevaar JC, Dekker FW et al. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) -2. Am. J. Kidney Dis. 2003 41 : 1293 302.
3. Szeto CC, Wong T, Leung C et al. Importance of dialysis adequacy in mortality and morbidity of Chinese CAPD patients. Kidney Int. 2000 58 : 400 407.
4. Rocco M, Soucie JM, Pastan S, Mcclellan WM. Peritoneal dialysis adequacy and risk of death. Kidney Int. 2000 58 : 446 57.
5. Churchill DN, Taylor DW, Keshaviah PR for the Canusa Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes. J. Am. Soc. Nephrol. 1996 7 : 198 207.
6. Bargman JM, Thorpe KE, Churchill DN for the Canusa Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis; A reanalysis of the CANUSA study. J. Am. Soc. Nephrol. 2001 12 : 2158 62.
7. Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients. Am. J. Kidney Dis. 2001 38 : 85 90.
8. Termorshuizen F, Dekker FW, van Manen JG et al. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: An analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J. Am. Soc. Nephrol. 2004 15 : 1061 70.
9. Eknoyan G, Beck GJ, Cheung AK et al. for the Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N. Engl. J. Med. 2002 347 : 2010 19.
10. Bammens B, Evenpoel P, Verbeke K, Vanrenterghem Y. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int. 2003 64 : 2238 43.
11. Bammens B, Evenpoel P, Verbeke K, Vanrenterghem Y. Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients. Am. J. Kidney Dis. 2005 46 : 512 19.
12. Mccarthy JT, Williams AW, Johnson WJ. Serum beta 2-microglobulin concentration in dialysis patients: Importance of intrinsic renal function. J. Lab. Clin. Med. 1994 123 : 495 505.
13. Lopez-Menchero R, Miguel A, Garcia-Ramon R, Perez-Contreras J, Girbes V. Importance of residual renal function in continuous ambulatory peritoneal dialysis: Its influence on different parameters of renal replacement treatment. Nephron 1999 83 : 219 25.
14. Mistry CD, O'Donoghue DJ, Nelson R, Gokal R, Ballardie FW. Kinetic and clinical studies of beta 2 microglobulin in continuous peritoneal dialysis: Influence of renal and enhanced peritoneal clearances using glucose polymer. Nephrol. Dial. Transplant. 1990 5 : 513 19.
15. Catizone L, Cocchi R, Fusaroli M, Zucchelli P. Relationship between plasma beta-2 microglobulin and residual diuresis and continuous ambulatory peritoneal dialysis and hemodialysis patients. Perit. Dial. Int. 1993 13 (Suppl. 2 S523 6.
16. Montenegro J, Martinez I, Saracho R, Gonzalez R. Beta 2 microglobulin in CAPD. Adv. Perit. Dial. 1992 8 : 369 72.
17. Amici G, Virga G, Da Rin G et al. Serum beta-2-microglobulin level and residual renal function in peritoneal dialysis. Nephron 1993 65 : 469 71.
18. Ates K, Nergizoglu G, Keven K et al. Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int. 2001 60 : 767 76.
19. Konings CJ, Kooman JP, Schonck M et al. Fluid status in CAPD patients is related to peritoneal transport and residual renal function: Evidence from a longitudinal study. Nephrol. Dial. Transplant. 2003 18 : 797 803.
20. Menon MK, Naimark DM, Bargman JM, Vas SI, Oreopoulos DG. Long-term blood pressure control in a cohort of peritoneal dialysis patients and its association with residual renal function. Nephrol. Dial. Transplant. 2001 16 : 2207 13.
21. Wang AY, Wang M, Woo J et al. A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int. 2002 62 : 639 47.
22. Wang AY, Wang M, Woo J et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J. Am. Soc. Nephrol. 2004 15 : 2186 94.
23. Wang AY, Lam CW, Wang M et al. Circulating soluble vascular cell adhesion molecule 1: Relationships with residual renal function, cardiac hypertrophy, and outcome of peritoneal dialysis patients. Am. J. Kidney Dis. 2005 45 : 715 29.
24. Chung SH, Heimburger O, Stenvinkel P, Qureshi AR, Lindholm B. Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol. Dial. Transplant. 2003 18 : 590 97.
25. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int. 2001 59 : 407 14.
26. Aguilera A, Codoceo R, Bajo MA et al. Helicobacter pylori infection: A new cause of anorexia in peritoneal dialysis patients. Perit. Dial. Int. 2001 21 (Suppl. 3 S152 6.
27. Wang AY, Sea MM, Ip R et al. Independent effects of residual renal function and dialysis adequacy on actual dietary protein, calorie, and other nutrient intake in patients on continuous ambulatory peritoneal dialysis. J. Am. Soc. Nephrol. 2001 12 : 2450 57.
28. Wang AY, Sea MM, Ip R et al. Independent effects of residual renal function and dialysis adequacy on dietary micronutrient intakes in patients receiving continuous ambulatory peritoneal dialysis. Am. J. Clin. Nutr. 2002 76 : 569 76.
29. Caravaca F, Arrobas M, Dominguez C. Influence of residual renal function on dietary protein and caloric intake in patients on incremental peritoneal dialysis. Perit. Dial. Int. 1999 19 : 350 56.
30. Shemin D, Bostom AG, Lambert C, Hill C, Kitsen J, Kliger AS. Residual renal function in a large cohort of peritoneal dialysis patients: Change over time, impact on mortality and nutrition. Perit. Dial. Int. 2000 20 : 439 44.
31. Page DE, Knoll GA, Cheung V. The relationship between residual renal function, protein catabolic rate and phosphate and magnesium levels in peritoneal dialysis patients. Adv. Perit. Dial. 2002 18 : 189 91.
32. Merkus MP, Jager KJ, Dekker FW et al. Quality of life in patients on chronic dialysis: Self-assessment 3 months after the start of treatment. Am. J. Kidney Dis. 1997 24 : 584 92.
33. Merkus MP, Jager KJ, Dekker FW et al. Physical symptoms and quality of life in patients on chronic dialysis: Results of The Netherlands Cooperative Study on Adequacy of Dialysis (NECOSAD). Nephrol. Dial. Transplant. 1999 14 : 1163 70.
34. Dixit MP, Cabansag MR, Piscitelli J, Greifer I, Silverstein DM. Serum beta-2- microglobulin and immunoglobulin levels in young hemodialysis patients. Pediatr. Nephrol. 1999 13 : 139 42.
35. Pickett TM, Cruickshank A, Greenwoood RN, Taube D, Davenport A, Farrington K. Membrane flux not biocompatibility determines beta-2-microglobulin levels in hemodialysis patients. Blood Purif. 2002 20 : 161 6.
36. Suda T, Hiroshige K, Ohta T et al. The contribution of residual renal function to overall nutritional status in chronic haemodialysis patients. Nephrol. Dial. Transplant. 2000 15 : 396 401.
37. Erkan E, Moritz M, Kaskel F. Impact of residual renal function in children on hemodialysis. Pediatr. Nephrol. 2001 16 : 858 61.
38. Morduchowicz G, Winkler J, Zabludowski JR, Boner G. Effects of residual renal function in haemodialysis patients. Int. Urol. Nephrol. 1994 26 : 125 31.
39. Ravid M, Lang R, Robson M. The importance of daily urine Volume and residual renal function in patients treated by chronic hemodialysis. Dial. Transplant. 1980 9 : 763 5.
40. Hartmann J, Fricke H, Schiffl H. Biocompatible membranes preserve residual renal function in patients undergoing regular hemodialysis. Am. J. Kidney Dis. 1997 30 : 366 73.
41. Canaud B, Chenine L, Leray-Moragues H, Wiesen H, Tetta C. Residual renal function and dialysis modality: Is it really beneficial to preserve residual renal function in dialysis patients? Nephrology 2006 11 : 292 6.
42. Gunal AI, Kirciman E, Guler M, Yavuzkir M, Celiker H. Should the preservation of residual renal function cost Volume overload and its consequence left ventricular hypertrophy in new hemodialysis patients? Ren. Fail. 2004 26 : 405 9.
43. Rottembourg J, Issad B, Gallego JL et al. Evolution of residual renal function in patients undergoing maintenance hemodialysis or continuous peritoneal dialysis. Proc. Eur. Dial. Transplant. Assoc. 1983 19 : 397 403.
44. Cancarini GC, Brunori G, Camerini C, Brasa S, Manili L, Maiorca R. Renal function recovery and maintenance of residual diuresis in CAPD and hemodialysis. Perit. Dial. Bull. 1986 6 : 77 9.
45. Lysaght MJ, Vonesh EF, Gotch F et al. The influence of dialysis treatment modality on decline of remaining renal function. ASAIO. Trans. 1991 37 : 598 604.
46. Moist LM, Port FK, Orzol SM et al. Predictors of loss of residual renal function among new dialysis patients. J. Am. Soc. Nephrol. 2000 11 : 556 64.
47. Misra M, Vonesh E, Van Stone JC, Moore HL, Prowant B, Nolph KD. Effect of cause and time of dropout on the residual GFR: A comparative analysis of the decline of GFR on dialysis. Kidney Int. 2001 59 : 754 63.
48. Lang SM, Bergner A, Topfer M et al. Preservation of residual renal function in dialysis patients: Effects of dialysis-technique-related factors. Perit. Dial. Int. 2001 21 : 52 7.
49. Jansen MA, Hart AA, Korevaar JC et al. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int. 2002 62 : 1046 53.
50. Mckane W, Chandna SM, Tattersall JE, Greenwook RN, Farrington K. Identical decline of residual renal function in high-flux biocompatible hemodialysis and CAPD. Kidney Int. 2002 61 : 256 65.
51. Hakim RM, Pontzer MA, Tilton D, Lazarus JM, Gottlieb MN. Effects of acetate and bicarbonate dialysate in stable chronic dialysis patients. Kidney Int. 1985 28 : 535 40.
52. La Greca G, Feriani M, Bragantini L, Petrosino L, Santoro A, Altieri P. Effects of acetate and bicarbonate dialysate on vascular stability: A prospective multicentre study. Int. J. Artif. Organs 1987 10 : 157 62.
53. Caramelo C, Alcazar R, Gallar P et al. Choice of dialysis membrane does not influence the outcome of residual renal function in haemodialysis patients. Nephrol. Dial. Transplant. 1994 9 : 675 7.
54. Van Stone JC. The effect of dialyser membrane and etiology of kidney disease on the preservation of residual renal function in chronic hemodialysis patients. ASAIO. J. 1995 41 : 713 16.
55. Hakim RM, Wingard RL, Husni L, Parker RA, Parker TF III. The effect of membrane biocompatibility on plasma β2-microglobulin levels in chronic hemodialysis patients. J. Am. Soc. Nephrol. 1996 7 : 472 8.
56. McCarthy JT, Jenson BM, Squillace DP, Williams AW. Improved preservation of residual renal function in patients undergoing chronic hemodialysis using polysulfone dialysers. Am. J. Kidney Dis. 1997 29 : 576 83.
57. Stannat S, Bahlmann J, Kiessling D, Koch KM, Deicher H, Peter HH. Complement activation during hemodialysis. Comparison of polysulfone and cuprophan membranes. Contrib. Nephrol. 1985 46 : 102 8.
58. Woffindin C, Hoenich NA. Blood-membrane interactions during haemodialysis with cellulose and synthetic membranes. Biomaterials 1988 9 : 53 7.
59. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol. Dial. Transplant. 2002 17 : 1814 18.
60. van Olden RW, Krediet RT, Struijk DG, Arisz L. Measurement of residual renal function in patients treated with continuous ambulatory peritoneal dialysis. J. Am. Soc. Nephrol. 1996 7 : 745 50.
61. van Olden RW, van Acker AC, Koomen GCM, Krediet RT, Arisz L. Time course of inulin and creatinine clearance in the interval between two haemodialysis treatments. Nephrol. Dial. Transplant. 1995 10 : 2274 80.
62. Milutinovic J, Cutler RE, Hoover P, Meijsen B, Scribner BH. Measurement of residual glomerular filtration rate in the patient receiving repetitive hemodialysis. Kidney Int. 1975 8 : 185 90.
63. Hemodialysis Adequacy 2006 Workgroup. KDOQI Clinical practice guidelines for hemodialysis adequacy, Update 2006. Am. J. Kidney Dis. 2006 48 (Suppl. 1 S2 90.
64. European Best Practice Guidelines Working Group. European Best Practice Guidelines for Haemodialysis (Part 1). Nephrol. Dial. Transplant. 2002 17 (Suppl. 7 1 111.
65. Depner TA. Haemodialysis adequacy: Basic essentials and practical points for the nephrologists in training. Hemodial. Int. 2005 9 : 241 54.
66. Gotch FA. The current place of urea kinetic modeling with respect to different dialysis modalities. Nephrol. Dial. Transplant. 1998 13 (Suppl. 6 S10 14.
67. Singhal MK, Bhaskaran S, Vidgen E, Bargman JM, Vas SI, Oreopoulos DG. Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit. Dial. Int. 2000 20 : 429 38.
68. Shin SK, Noh H, Kang SW et al. Risk factors influencing the decline of residual renal function in continuous ambulatory peritoneal dialysis patients. Perit. Dial. Int. 1999 19 : 138 42.
69. Holley JL, Aslam N, Bernardini J, Fried L, Piraino B. The influence of demographic factors and modality on loss of residual renal function in incident peritoneal dialysis patients. Perit. Dial. Int. 2001 21 : 302 5.
70. Hidaka H, Nakao T. Preservation of residual renal function and factors affecting its decline in patients on peritoneal dialysis. Nephrology (Carlton) 2003 8 : 184 91.
71. Johnson DW, Mudge DW, Sturtevant JM et al. Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit. Dial. Int. 2003 23 : 276 83.
72. Shemin D, Maaz D, St Pierre D, Kahn SI, Chazan JA. Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients. Am. J. Kidney Dis. 1999 34 : 14 20.
73. Hufnagel G, Michel C, Queffeulou G, Skhiri H, Damieri H, Mignon F. The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol. Dial. Transplant. 1999 14 : 1224 8.
74. Moranne O, Willoteaux S, Pagniez D, Dequiedt P, Boulanger E. Effect of iodinated contrast agents on residual renal function in PD patients. Nephrol. Dial. Transplant. 2006 21 : 1040 45.
75. Iest GC, Vanholder RC, Ringoir SM. Loss of residual renal function in patients on regular haemodialysis. Int. J. Artif. Organs 1989 12 : 159 64.
76. van Olden RW, Guchelaar HJ, Strujik DG, Krediet RT, Arisz L. Acute effects of high-dose frusemide on residual renal function in CAPD patients. Perit. Dial. Int. 2003 23 : 339 47.
77. Medcalf JF, Harris KPG, Walls J. Role of diuretics in the preservation of renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int. 2001 59 : 1128 33.
78. Li PK, Chow KM, Wong YH, Leung CB, Szeto CC. Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. Ann. Int. Med. 2003 139 : 105 12.
79. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am. J. Kidney Dis. 2004 43 : 1056 64.